BioSpace News Archive

Q-CTRL, a startup that applies the principles of control engineering to accelerate the development of quantum technology, and Quantum Machines, creator of the first complete hardware and software solution for the control and operation of quantum computers, today announced a global commercial partnership to integrate Q-CTRL’s firmware into Quantum Machines’ quantum hardware platform.

Fountain Therapeutics (“Fountain”), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced it has moved its corporate headquarters to Lilly Gateway Labs in South San Francisco upon selection by Eli Lilly and Company.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that an independent analyst report by Ari Zoldan was published on Seeking Alpha, a crowd-sourced content service for financial markets.

Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the Cantor Virtual Global Healthcare Conference.

A recent study published in the Journal of the American Medical Association Neurology demonstrates for the first time the feasibility of Hyperfine’s Swoop™ Portable MRI System to obtain bedside neuroimaging for critically-ill patients in the intensive care unit settings.

Medicine X today announced the launch of Eczema Xplained, its first illustrated story in the U.S. on atopic dermatitis, the most common form of eczema.

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), Waisman Biomanufacturing and Goodwin Biotechnology, Inc.

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in September.

Mycenax Biotech, Inc. (4726.TWO), a pioneer of biopharmaceutical development in Taiwan, today announced its adoption of the Berkeley Lights Platform for cell line development. Berkeley Lights, Inc., (Nasdaq: BLI), a leader in Digital Cell Biology, continues to see adoption of the system in Asia Pacific, as Mycenax becomes the first company in Taiwan to use the technology.

Paradise Genomics announced that it has advanced the development of their whole blood-based assay for gastric cancer by translating a gene expression profile associated with the disease into a high-throughput and cost-effective real-time PCR (RT-PCR) test.